European Companies Search Engine

EU funding (€8,468,780): Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours Hor 28 May 2026 EU Research and Innovation programme "Horizon"

Overview

Text

Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours

Childhood cancer is the leading cause of disease-related death in children, with high-risk neuroblastoma and other aggressive paediatric solid tumours representing a critical unmet need. Despite multimodal therapy, over half of children with relapsed or refractory disease do not achieve long-term survival, and those who do often suffer severe, lifelong toxicities. There is an urgent need for safer and more effective therapies. Ibrilatazar (ABTL0812) is a first-in-class, orally administered anticancer agent that induces tumour cell death through endoplasmic reticulum stress and cytotoxic autophagy. Unlike conventional genotoxic chemotherapies, it spares DNA, offering a potentially safer profile highly relevant in children. In adult patients with advanced solid tumours, ibrilatazar has shown an excellent safety record and early efficacy in Phase I/II trials, with long-term stabilisation in heavily pre-treated patients, thereby supporting its evaluation in the paediatric population. Preclinical studies in neuroblastoma models, including MYCN-amplified and chemoresistant cell lines, demonstrate that ibrilatazar reduces tumour growth, downregulates MYCN expression, and enhances standard chemotherapies and differentiating agents. Building on this evidence, PHOENIX will conduct a first-in-child, multicentre Phase I/II clinical trial of ibrilatazar in relapsed/refractory neuroblastoma and other aggressive solid tumours. The trial will test combinations with irinotecan-temozolomide and selected immunotherapies (anti-GD2, anti-VEGF), aligned with our preclinical findings. In parallel, a comprehensive translational programme will integrate pharmacokinetic, pharmacodynamic, genomic, and immunological biomarker studies, aiming to enable patient stratification, early treatment monitoring, and improved trial inclusiveness by addressing social determinants of health. Thus, PHOENIX seeks to deliver a safer, more effective therapeutic alternative for children with high-risk cancers. This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment - innovative clinical trials for paediatric cancer.


Funded Companies:

Company name Funding amount
Ability Pharmaceuticals SA €1,892,625
Children's Health Ireland €220,299
Echalliance CLG €342,125
Ecrin European Clinical Research Infrastructure Network €1,693,271
Fakultni Nemocnice Brno €37,500
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca €2,141,224
Fundación Cris de Investigación para Vencer El Cáncer €80,000
Fundacion para La Investigacion Biomedica del Hospital Universiatrio La Paz €0.00
Fundacion para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus €1,095,125
Fundacion para La Investigacion de Malaga en Biomedicina y Salud €0.00
Institut Curie €280,807
Institut Gustave Roussy €100,000
Masarykova Univerzita €0.00
Region Hovedstaden €70,750
Shine 2Europe Lda. €296,625
Universitat Autonoma de Barcelona €218,430

Source: https://cordis.europa.eu/project/id/101289276

The filing refers to a past date, and does not necessarily reflect the current state.